SEC Form 4
Braveheart Bio, Inc. (BRVE) insider trading
In the 12 months to Nov 19, 2026, 12 BRVE insiders reported open-market purchases of $159.0M across 12 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $159.0M
- 12 filings
Who traded BRVE, and when
- Purchase
BRVE daily close from Aug 6, 2026 to Nov 18, 2026, between $17.42 and $30.00, last $18.53. 0 sale and 12 purchase filings by 12 insiders, marked at their filing dates. Erez Chimovits, Director: bought $34.9M across 1 filing, first filed Aug 11, 2026, last Aug 11, 2026. Forbion Ventures VII Management B.V., 10% owner: bought $34.6M across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. Forbion Growth III Management B.V., 10% owner: bought $30.2M across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. ORBIMED ADVISORS LLC, Director: bought $30.0M across 1 filing, first filed Aug 11, 2026, last Aug 11, 2026. Benjamin A. Horowitz, 10% owner: bought $19.8M across 1 filing, first filed Aug 11, 2026, last Aug 11, 2026. OrbiMed Capital GP IX LLC, Director: bought $4.9M across 1 filing, first filed Aug 11, 2026, last Aug 11, 2026. Christopher Viehbacher, Director: bought $1.5M across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. Travis Murdoch, CEO and President: bought $1.5M across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. David Charles Lubner, Director: bought $1.0M across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. James Paul Rickey, Chief Financial Officer: bought $500.0K across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. David I. Malek, Director: bought $75.0K across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. Michele A. Anderson, Chief Development Officer: bought $20.0K across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026.
Largest mark · tap a row for others
Erez Chimovits · Director
Purchase $34,920,000
1,940,000 shares at $18.00 avg
Filed Aug 11, 2026 · traded Aug 7
Close on filing date $25.01
Erez Chimovits · Director
Director
$34.9M boughtForbion Ventures VII Management B.V. · 10% owner
10% owner
$34.6M boughtForbion Growth III Management B.V. · 10% owner
10% owner
$30.2M boughtORBIMED ADVISORS LLC · Director
Director
$30.0M boughtBenjamin A. Horowitz · 10% owner
10% owner
$19.8M boughtOrbiMed Capital GP IX LLC · Director
Director
$4.9M boughtChristopher Viehbacher · Director
Director
$1.5M boughtTravis Murdoch · CEO and President
CEO and President
$1.5M boughtDavid Charles Lubner · Director
Director
$1.0M boughtJames Paul Rickey · Chief Financial Officer
Chief Financial Officer
$500.0K boughtDavid I. Malek · Director
Director
$75.0K boughtMichele A. Anderson · Chief Development Officer
Chief Development Officer
$20.0K boughtOpen-market trades
12 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Erez Chimovits | Director | — | $34.9M | 1 | — | |
| Forbion Ventures VII Management B.V. | 10% owner | — | $34.6M | 1 | — | |
| Forbion Growth III Management B.V. | 10% owner | — | $30.2M | 1 | — | |
| ORBIMED ADVISORS LLC | Director | — | $30.0M | 1 | — | |
| Benjamin A. Horowitz | 10% owner | — | $19.8M | 1 | — | |
| OrbiMed Capital GP IX LLC | Director | — | $4.9M | 1 | — | |
| Christopher Viehbacher | Director | — | $1.5M | 1 | — | |
| Travis Murdoch | CEO and President | — | $1.5M | 1 | — | |
| David Charles Lubner | Director | — | $1.0M | 1 | — | |
| James Paul Rickey | Chief Financial Officer | — | $500.0K | 1 | — | |
| David I. Malek | Director | — | $75.0K | 1 | — | |
| Michele A. Anderson | Chief Development Officer | — | $20.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | ORBIMED ADVISORS LLC Director | Purchase | 1,666,667 | $18.00 | $30.0M | 11,901,826 | |
traded | OrbiMed Capital GP IX LLC Director | Purchase | 273,333 | $18.00 | $4.9M | 273,333 | |
traded | Erez Chimovits Director | Purchase | 1,940,000 | $18.00 | $34.9M | 273,333 | |
traded | Benjamin A. Horowitz 10% owner | Purchase | 1,100,000 | $18.00 | $19.8M | 10,232,420 | |
traded | Forbion Ventures VII Management B.V. 10% owner | Purchase | 1,920,000 | $18.00 | $34.6M | 11,640,546 | |
traded | Forbion Growth III Management B.V. 10% owner | Purchase | 1,680,000 | $18.00 | $30.2M | 10,185,478 | |
traded | David Charles Lubner Director | Purchase | 55,555 | $18.00 | $1.0M | 55,555 | |
traded | Travis Murdoch CEO and President | Purchase | 83,333 | $18.00 | $1.5M | 2,940,670 | |
traded | Michele A. Anderson Chief Development Officer | Purchase | 1,111 | $18.00 | $20.0K | 332,161 | |
traded | David I. Malek Director | Purchase | 4,166 | $18.00 | $75.0K | 533,845 | |
traded | Christopher Viehbacher Director | Purchase | 83,333 | $18.00 | $1.5M | 609,519 | |
traded | James Paul Rickey Chief Financial Officer | Purchase | 27,777 | $18.00 | $500.0K | 520,927 |
GET /stocks/filings/vX/form-4?tickers=BRVE&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BRVE"
],
"issuer_cik": "0002131524",
"owner_cik": "0001889898",
"accession_number": "0001231919-26-000859",
"form_type": "4",
"filing_date": "2026-08-11",
"period_of_report": "2026-08-07",
"issuer_name": "Braveheart Bio, Inc.",
"issuer_trading_symbol": "BRVE",
"owner_name": "AH Equity Partners Bio IV, L.L.C.",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-07",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1100000,
"transaction_price_per_share": 18,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 10232420,
"transaction_value": 19800000,
"direct_or_indirect": "I",
"nature_of_ownership": "By AH Bio Fund IV, L.P.",
"footnotes": [
{
"id": "F2",
"description": "The reported securities are held by AH Bio Fund IV, L.P. (\"AH Bio Fund IV\"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. (\"AH EP Bio IV\") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee."
},
{
"id": "F3",
"description": "(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any."
}
]
},
{
"tickers": [
"BRVE"
],
"issuer_cik": "0002131524",
"owner_cik": "0001055951",
"accession_number": "0000947871-26-000782",
"form_type": "4",
"filing_date": "2026-08-11",
"period_of_report": "2026-08-07",
"issuer_name": "Braveheart Bio, Inc.",
"issuer_trading_symbol": "BRVE",
"owner_name": "ORBIMED ADVISORS LLC",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-07",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1666667,
"transaction_price_per_share": 18,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 11901826,
"transaction_value": 30000006,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnotes",
"footnotes": [
{
"id": "F2",
"description": "Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."
},
{
"id": "F3",
"description": "These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX."
},
{
"id": "F5",
"description": "This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 6 records
- Other6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Braveheart Bio, Inc.'s CEO sold stock?
No. Travis Murdoch (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is BRVE’s insider data?
These are BRVE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track BRVE insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BRVE every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.